Spots Global Cancer Trial Database for CT Perfusion Scans in Detecting Changes in Blood Flow to the Liver After Portal Vein Embolization

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: CT Perfusion Scans in Detecting Changes in Blood Flow to the Liver After Portal Vein Embolization

Official Title: To Evaluate Perfusion Changes to the Liver Following Pre-Operative Portal Vein Embolization for Patients With Liver Cancer

Study ID: NCT03990623

Conditions

Liver and Intrahepatic Bile Duct Carcinoma

Interventions

Computed Tomography Perfusion Imaging

Liver Biopsy

Study Description

Brief Summary: This trial studies the use of computed tomography (CT) perfusion scans in detecting changes in blood flow to the liver after portal vein embolization in patients with liver cancer. CT perfusion scans use a standard contrast drug given by vein to measure blood flow to the liver. CT perfusion scans may predict the rate and amount of growth of new, healthy tissue on one side of the liver after a portal vein embolization and detect change to the size of the liver tumor as result of the procedure.

Detailed Description: PRIMARY OBJECTIVES: I. To assess whether perfusion changes to the liver following portal vein embolization (PVE) correlate with hypertrophy of the future liver remnant (FLR). SECONDARY OBJECTIVES: I. To assess perfusion changes to liver tumors following PVE. II. To assess whether PVE may affect tumor growth. OUTLINE: Prior to PVE, patients undergo CT perfusion scan of the liver and liver biopsy over 15 minutes. Patients undergo a second CT perfusion scan immediately after PVE and a third CT perfusion scan 3-6 weeks post PVE.